Mayne Pharma Group Ltd (MAYNF)
4.54
0.00 (0.00%)
USD |
OTCM |
Apr 23, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 386.24M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 72.62% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.113 |
| Price to Book Value | 1.035 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0668 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 91.53% |
Profile
| Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women’s health products in the US. International’s segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products. |
| URL | http://www.maynepharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 26, 2024 |
| Last Earnings Release | Feb. 26, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 18, 2023 |
Ratings
Profile
| Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women’s health products in the US. International’s segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products. |
| URL | http://www.maynepharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 26, 2024 |
| Last Earnings Release | Feb. 26, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 18, 2023 |